Clinical features and long‐term outcomes in pediatric cyclic vomiting syndrome: A 9‐year experience at three tertiary academic centers

2021 ◽  
Author(s):  
Valeria Dipasquale ◽  
Raffaele Falsaperla ◽  
Annarita Bongiovanni ◽  
Martino Ruggieri ◽  
Claudio Romano
Keyword(s):  
Clinical Features ◽  
Cyclic Vomiting Syndrome ◽  
Long Term Outcomes ◽  
Cyclic Vomiting

scholarly journals Cannabinoid hyperemesis syndrome: definition, pathophysiology, clinical spectrum, insights into acute and long-term management

2020 ◽  
Vol 68 (8) ◽  
pp. 1309-1316
Author(s):  
Mahesh Gajendran ◽  
Joshua Sifuentes ◽  
Mohammad Bashashati ◽  
Richard McCallum
Keyword(s):  
Symptom Control ◽  
Well Being ◽  
Clinical Entity ◽  
Cyclic Vomiting Syndrome ◽  
Cannabinoid Hyperemesis Syndrome ◽  
Acute Attacks ◽  
Hot Baths ◽  
Term Management ◽  
Cyclic Vomiting

Although cannabinoid hyperemesis syndrome (CHS) was first reported more than 15 years ago, it still remains an unfamiliar clinical entity among physicians worldwide. CHS is categorized by Rome IV classification as a functional gastroduodenal disorder. It is characterized by stereotypical episodic vomiting in the setting of chronic, daily cannabis use, with cycles decreasing by the cessation of cannabis. CHS is also associated with abdominal pain reduced by hot baths and showers with comparative well-being between attacks. Thus, its clinical presentation resembles ‘classic’ cyclic vomiting syndrome, but eliciting a cannabis history is crucial in diagnosing this entity. In acute attacks, parenteral benzodiazepines are very effective. For prevention and long-term management, tricyclic antidepressants such as amitriptyline are the mainstay of therapy requiring doses in the range of 50–200 mg/d to achieve symptom control. In addition, counseling to achieve marijuana cessation, accompanied by antianxiety medications, is necessary for sustaining clinical outcomes. Once the patient is in remission and off marijuana for a period of 6–12 months, then tapering the dose of amitriptyline can be implemented, with the goal of no therapy being achieved in the majority of patients over time. With the legalization of marijuana in many states, CHS will become an increasingly prevalent clinical entity, so educating about CHS is an important goal, particularly for emergency department physicians who generally first encounter these patients.

Clinical features and long‐term outcomes of lower esophageal sphincter‐dependent and lower esophageal sphincter‐independent jackhammer esophagus

2018 ◽  
Vol 31 (2) ◽  
pp. e13507 ◽  
Author(s):  
Allon Kahn ◽  
Mohanad T. Al‐Qaisi ◽  
Robert A. Obeid ◽  
David A. Katzka ◽  
Karthik M. Ravi ◽  
...  
Keyword(s):  
Lower Esophageal Sphincter ◽  
Clinical Features ◽  
Long Term Outcomes ◽  
Esophageal Sphincter

scholarly journals Lateral Ventricular Meningiomas: Clinical Features, Radiological Findings and Long-Term Outcomes

2021 ◽  
Vol Volume 13 ◽  
pp. 6089-6099
Author(s):  
Haibo Teng ◽  
Zhiyong Liu ◽  
Ouying Yan ◽  
Wenbo He ◽  
Danyang Jie ◽  
...  
Keyword(s):  
Clinical Features ◽  
Long Term Outcomes ◽  
Radiological Findings

scholarly journals Changes in the Clinical Features and Long-term Outcomes of Colonic Diverticulitis in Japanese Patients

2017 ◽  
Vol 56 (22) ◽  
pp. 2971-2977 ◽  
Author(s):  
Akira Mizuki ◽  
Masayuki Tatemichi ◽  
Atsushi Nakazawa ◽  
Nobuhiro Tsukada ◽  
Hiroshi Nagata ◽  
...  
Keyword(s):  
Clinical Features ◽  
Japanese Patients ◽  
Colonic Diverticulitis ◽  
Long Term Outcomes

Clinical Features and Long-Term Outcomes of Unilateral Moyamoya Disease

2016 ◽  
Vol 96 ◽  
pp. 474-482 ◽  
Author(s):  
Qian Zhang ◽  
Rong Wang ◽  
Yaping Liu ◽  
Yan Zhang ◽  
Shuo Wang ◽  
...  
Keyword(s):  
Clinical Features ◽  
Moyamoya Disease ◽  
Long Term Outcomes ◽  
Unilateral Moyamoya Disease

scholarly journals Clinical features and long-term outcomes of moyamoya disease: a single-center experience with 528 cases in China

2015 ◽  
Vol 122 (2) ◽  
pp. 392-399 ◽  
Author(s):  
Xing-ju Liu ◽  
Dong Zhang ◽  
Shuo Wang ◽  
Yuan-li Zhao ◽  
Mario Teo ◽  
...  
Keyword(s):  
Clinical Features ◽  
Moyamoya Disease ◽  
Positive Impact ◽  
Chinese Patients ◽  
Single Center ◽  
Long Term Outcomes ◽  
Kaplan Meier ◽  
Significant Difference ◽  
Revascularization Procedures

OBJECT The aim of this study was to describe the baseline clinical features and long-term outcomes of patients with moyamoya disease (MMD) based on a 25-year period at a single center in China. METHODS  Data obtained in 528 consecutive patients with MMD treated at the authors' hospital from 1984 to 2010 were reviewed retrospectively. Events of transient ischemic attack, new infarction, and hemorrhage were included. The Kaplan-Meier risk of stroke was calculated. RESULTS  The mean (± SD) patient age was 26 ± 13 years (range 2–67 years), and the female/male ratio was 0.9:1. There were 332 cases of ischemia and 196 hemorrhages. Adults had a higher rate of bleeding than children (50.7% vs 14.0%, respectively; p < 0.001). One hundred twenty-two patients were treated conservatively, and 406 patients underwent revascularization procedures. Of 528 patients, 331 (62.7%) had at least 1 year of follow-up (median 39.5 months) and data from these patients were analyzed. Rebleeding and mortality rates in patients with hemorrhagic MMD (n = 104) were higher than in those with ischemic MMD (n = 227) (26.9% vs 2.2% [p < 0.001] and 4.8% vs 0.4% [p < 0.05], respectively). Twenty-five of 60 (41.7%) conservatively treated patients and 8 of 271 (2.9%) surgically treated patients experienced rebleeding events, a difference that was significant in the Kaplan-Meier curve of rebleeding (p < 0.01). An improvement in perfusion was found in 164 of 224 (73.2%) surgically treated patients 1 month after discharge. However, there was no significant difference in the rate of ischemic events in the surgical and conservative groups (18.8% and 28.3%, respectively; p = 0.09). Among the 104 hemorrhagic cases, rebleeding attacks were observed in 25 patients in the nonsurgical group (n = 60) and 3 patients in the surgical group (n = 44) (41.7% and 6.8%, respectively; OR 9.7 [95% CI 2.7–35.0]; p < 0.01). CONCLUSIONS  There was no difference in the sex distribution of Chinese patients with MMD. Patients with hemorrhagic MMD had a much higher rate of rebleeding and poorer prognosis than those with the ischemic type. Surgical revascularization procedures can improve cerebral perfusion and have a positive impact in preventing rebleeding in patients with hemorrhagic MMD.

Clinical features and long-term outcomes of pediatric intraventricular meningiomas: data from a single neurosurgical center

2017 ◽  
Vol 41 (2) ◽  
pp. 525-530 ◽  
Author(s):  
Zhicen Li ◽  
Hao Li ◽  
Yuming Jiao ◽  
Ji Ma ◽  
Shuo Wang ◽  
...  
Keyword(s):  
Clinical Features ◽  
Long Term Outcomes
Sign in / Sign up

Export Citation Format

Share Document